NDAORAL-28TABLET
Approved
Nov 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PREMPHASE 14/14 (conjugated estrogens and medroxyprogesterone acetate) by Pfizer is estrogen receptor agonists [moa]. First approved in 1995.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREMPHASE 14/14 is an oral combination hormone replacement therapy (HRT) containing conjugated estrogens and medroxyprogesterone acetate. It works as an estrogen receptor agonist to manage menopausal symptoms by restoring hormone levels in postmenopausal women. The product uses a 28-day cyclic dosing regimen with two distinct tablet formulations.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), brand teams should expect transition planning and potential headcount optimization in coming years.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PREMPHASE 14/14 presents a defensive career scenario focused on protecting market share in a mature segment against generic entry and new competitors. Roles emphasize execution, relationship management, and managed decline rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on PREMPHASE 14/14 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.